Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers.

Autor: Fan D; Department of Radiation Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kang JJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fan M; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Wang H; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China., Lee A; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yu Y; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chen L; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jillian Tsai C; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., McBride SM; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Riaz N; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gelblum DY; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Neal BP; ProCure Proton Therapy Center, Somerset, NJ, USA., Fetten J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Dunn LA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Michel LS; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Boyle JO; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cohen MA; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Roman BR; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ganly I; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Singh B; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wong RJ; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sherman EJ; ProCure Proton Therapy Center, Somerset, NJ, USA., Lee NY; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: leen2@mskcc.org.
Jazyk: angličtina
Zdroj: Oral oncology [Oral Oncol] 2020 May; Vol. 104, pp. 104641. Date of Electronic Publication: 2020 Mar 14.
DOI: 10.1016/j.oraloncology.2020.104641
Abstrakt: Objectives: Patients with prior irradiated head and neck cancer (HNC) who are ineligible for definitive retreatment have limited local palliative options. We report the largest series of the use of the Quad Shot (QS) regimen as a last-line local palliative therapy.
Materials and Methods: We identified 166 patients with prior HN radiation therapy (RT) treated with QS regimen (3.7 Gy twice daily over 2 consecutive days at 4 weeks intervals per cycle, up to 4 cycles). Palliative response defined by symptom(s) relief or radiographic tumor reduction, locoregional progression free survival (LPFS), overall survival (OS) and radiation-related toxicity were assessed.
Results: Median age was 66 years. Median follow-up for all patients was 6.0 months and 9.7 months for living patients. Overall palliative response rate was 66% and symptoms improved in 60% of all patients. Predictors of palliative response were > 2 year interval from prior RT and 3-4 QS cycles. Median LPFS was 5.1 months with 1-year LPFS 17.7%, and median OS was 6.4 months with 1-year OS 25.3%. On multivariate analysis, proton RT, KPS > 70, presence of palliative response and 3-4 QS cycles were associated with improved LPFS and improved OS. The overall Grade 3 toxicity rate was 10.8% (n = 18). No Grade 4-5 toxicities were observed.
Conclusion: Palliative QS is an effective last-line local therapy with minimal toxicity in patients with previously irradiated HNC. The administration of 3-4 QS cycles predicts palliative response, improved PFS, and improved OS. KPS > 70 and proton therapy are associated with survival improvements.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: